1. Home
  2. OPT vs AACT Comparison

OPT vs AACT Comparison

Compare OPT & AACT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OPT
  • AACT
  • Stock Information
  • Founded
  • OPT 1984
  • AACT 2021
  • Country
  • OPT Australia
  • AACT United States
  • Employees
  • OPT N/A
  • AACT N/A
  • Industry
  • OPT Biotechnology: Biological Products (No Diagnostic Substances)
  • AACT
  • Sector
  • OPT Health Care
  • AACT
  • Exchange
  • OPT Nasdaq
  • AACT Nasdaq
  • Market Cap
  • OPT 855.6M
  • AACT 690.3M
  • IPO Year
  • OPT 2020
  • AACT 2023
  • Fundamental
  • Price
  • OPT $5.09
  • AACT $11.06
  • Analyst Decision
  • OPT Strong Buy
  • AACT
  • Analyst Count
  • OPT 1
  • AACT 0
  • Target Price
  • OPT $12.00
  • AACT N/A
  • AVG Volume (30 Days)
  • OPT 40.1K
  • AACT 152.3K
  • Earning Date
  • OPT 03-03-2025
  • AACT 01-01-0001
  • Dividend Yield
  • OPT N/A
  • AACT N/A
  • EPS Growth
  • OPT N/A
  • AACT 48.19
  • EPS
  • OPT N/A
  • AACT 0.43
  • Revenue
  • OPT $261,859.00
  • AACT N/A
  • Revenue This Year
  • OPT N/A
  • AACT N/A
  • Revenue Next Year
  • OPT $46,864.26
  • AACT N/A
  • P/E Ratio
  • OPT N/A
  • AACT $25.72
  • Revenue Growth
  • OPT N/A
  • AACT N/A
  • 52 Week Low
  • OPT $1.79
  • AACT $10.48
  • 52 Week High
  • OPT $6.30
  • AACT $11.07
  • Technical
  • Relative Strength Index (RSI)
  • OPT 53.99
  • AACT 74.01
  • Support Level
  • OPT $4.77
  • AACT $11.04
  • Resistance Level
  • OPT $5.46
  • AACT $11.07
  • Average True Range (ATR)
  • OPT 0.32
  • AACT 0.02
  • MACD
  • OPT -0.11
  • AACT 0.00
  • Stochastic Oscillator
  • OPT 20.60
  • AACT 85.72

About OPT Opthea Limited

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.

About AACT Ares Acquisition Corporation II

Ares Acquisition Corp II is a blank check company.

Share on Social Networks: